佳士科技(300193.SZ):股東徐愛平將所持9.74%的表決權委託潘磊行使 公司實控人將變更為潘磊
格隆匯12月23日丨佳士科技(300193.SZ)公佈,公司近日收到持股5%以上股東潘磊和徐愛平簽署的《表決權委託協議》,徐愛平將所持有的公司47,058,006股股份(佔公司總股本的9.74%,佔公司剔除回購專用證券賬户中股份數量後的總股本的9.75%)的表決權在委託期限內無償且不可撤銷地委託潘磊行使,潘磊同意接受該委託。
《表決權委託協議》生效後,潘磊通過直接持股和接受表決權委託合計控制公司116,436,345股股份的表決權,佔公司剔除回購專用證券賬户中股份數量後的總股本的24.14%,公司由無實際控制人變更為潘磊為公司實際控制人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.